CHRNA9 as a New Prognostic Marker and Potential Therapeutic Target in Glioma

Xiaoshan Ma; Ren Geng; Yao Zhao; Wanzhen Xu; Yao Li; Yining Jiang; Yuanhao Liu; Liyan Zhao; Yunqian Li

doi:10.7150/jca.92080

CHRNA9 as a New Prognostic Marker and Potential Therapeutic Target in Glioma

J Cancer. 2024 Feb 24;15(8):2095-2109. doi: 10.7150/jca.92080. eCollection 2024.

Authors

Xiaoshan Ma¹, Ren Geng¹, Yao Zhao¹, Wanzhen Xu², Yao Li³, Yining Jiang¹, Yuanhao Liu¹, Liyan Zhao³, Yunqian Li¹

Affiliations

¹ Department of Neurosurgery, First Hospital of Jilin University, Changchun, China.
² Department of Neurosurgery, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
³ Department of Blood Transfusion, Second Hospital of Jilin University, Changchun, China.

Abstract

Background: The nicotinic acetylcholine receptor (nAChR) subunit alpha-9 (CHRNA9) is a unique cholinergic receptor, which is involved in tumor proliferation, apoptosis, metastasis and chemotherapy resistance. However, the correlation between the expression level of CHRNA9 in glioma and the clinical features and prognosis of glioma patients has not been clarified. The aim of this study was to verify the expression level of CHRNA9 in glioma and its effect on prognosis by bioinformatics methods. Methods: The RNA-seq data of glioma and normal samples were obtained from the TCGA and GTEx databases. Bioinformatics methods were utilized to analyze the differential expression of CHRNA9 between tumor samples and normal samples. The potential association between CHRNA9 and the clinicopathological features of glioma patients was also investigated. The Kaplan-Meier method and Cox regression were utilized to analyze the relationship between CHRNA9 expression level and survival time and prognostic value of glioma patients. Enrichment analysis was applied to predict gene function and signaling pathways associated with CHRNA9. Experimental verification was performed using tumor tissues and paracancerous tissues from glioma patients. Results: The results of bioinformatics analysis showed that the expression of CHRNA9 was increased in glioma tissues, correlating with poor prognosis and reduced patient survival time. Enrichment analysis suggested that CHRNA9 may interact with the JAK/STAT pathway. CHRNA9 was also found to be abnormally expressed in various other tumors and associated with the expression levels of numerous immune checkpoints in glioma. The findings from the analysis of clinical samples revealed that the expression levels of both mRNA and protein of CHRNA9 in glioma tissues were higher than those in paracancerous tissues. Similarly, the mRNA expression levels of STAT3, IL-6, and TNF-α, which are crucial factors in the STAT3 pathway, were elevated in glioma tissues compared to paracancerous tissues. Conclusion: CHRNA9 is a potential prognostic marker and immunotherapy target for glioma, with its mechanism of action potentially linked to the STAT3 pathway.

Keywords: CHRNA9; Glioma; Prognostic Marker; STAT3 Pathway; Therapeutic Target.